Recombinant hypoallergenic Equ c 1 polypeptides for use in the immunotherapy of horse allergy
US11679152B2 · kind B2 · utility
0Cited by
0References
11Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 4, 2019 |
| Grant date | Jun 20, 2023 |
| Priority date | — |
| Expiry date | May 12, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K14/47
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to specific modified Equ c 1 polypeptides and to the use of such polypeptides as hypoallergens for desensitizing against horse allergy. Particularly, the present invention provides a recombinant hypoallergenic Equ c 1 polypeptide comprising at least two amino acid modifications compared to a corresponding wild type Equ c 1 allergen, wherein the recombinant hypoallergenic polypeptide activates release of histamine from basophils to a degree less than the wild type allergen.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.